Sat Oct 05 03:32:57 UTC 2024: ## Precigen Stock Slides Below Key Average, Investors Eye Recent Earnings Miss and Analyst Reports

**New York, NY – October 4, 2024** – Precigen, Inc. (NASDAQ:PGEN), a biotechnology company specializing in gene and cell therapies, saw its share price drop below its 200-day moving average on Wednesday, closing at $0.97. The stock’s 200-day moving average stands at $1.36. The decline follows a period of mixed signals from analysts and a recent earnings miss.

Precigen reported a loss of $0.10 per share for the quarter ending August 14th, missing analysts’ expectations of a $0.09 loss. This, coupled with a negative return on equity and a negative net margin, has contributed to investor uncertainty.

While some analysts, such as HC Wainwright, remain optimistic with a “buy” rating and a target price of $4.00, others, like StockNews.com, have issued a “sell” rating. The consensus among analysts is a “Hold” with a target price of $7.00.

Adding to the volatility, insider trading activity has also been observed. SVP Jeffrey Thomas Perez recently purchased 58,823 shares of the company’s stock at an average price of $0.85 per share. Meanwhile, institutional investors have been both buying and selling PGEN shares. Notable recent moves include a 44.2% increase in holdings by SG Americas Securities LLC and a 12.4% increase by Renaissance Technologies LLC.

Precigen continues to develop its pipeline of gene and cell therapies targeting immuno-oncology, autoimmune disorders, and infectious diseases. However, the company faces ongoing challenges, including the recent earnings miss and the fluctuating analyst sentiment. Investors are closely watching how Precigen navigates these challenges and delivers on its clinical development goals.

Read More